Biotech: Page
-
Getty Images
NGM, now private, raises $122M for redrawn research plans
The Series A round was led by healthcare investor The Column Group, which made the 17-year-old biotechnology company private earlier this year.
By Delilah Alvarado • July 17, 2024 -
Getty Images
Cardurion raises another $260M to fuel heart drug pipeline
The financing, which ranks as one of the year’s larger private rounds, will help the startup advance a pair of drugs and potentially acquire other medicines.
By Jonathan Gardner • July 16, 2024 -
Explore the Trendline➔
National Institutes of Allergy and Infectious Diseases. (2016). "Human natural killer cell" [Micrograph]. Retrieved from Flickr.
TrendlineCell therapy
The continued emergence of CAR-T therapy has fueled research into next-generation approaches and new applications, such as its use in autoimmune diseases or in reprogramming cells inside the body.
By BioPharma Dive staff -
Courtesy of Vertex Pharmaceuticals
Vertex taps Orum to hunt for better ‘preconditioning’ drugs
The deal gives Vertex rights to use Orum’s ADC-like technology to discover gentler preparatory regimens for patients receiving intensive treatments like Casgevy.
By Gwendolyn Wu • July 16, 2024 -
Permission granted by Sionna Therapeutics
Sionna revives AbbVie’s cystic fibrosis drugs, eyeing a shot at Vertex
The startup says drugs AbbVie abandoned last year could form a combination regimen with “superior efficacy” to Vertex’s market-leading medicines.
By Ben Fidler • July 16, 2024 -
National Institute on Aging. (2017). "Beta-Amyloid Plaques and Tau in the Brain" [Image]. Retrieved from Flickr.
Asceneuron raises another $100M for Alzheimer’s drug development
The Merck KGaA spinout has a tau-regulating medicine it claims could be an “ideal therapy” for Alzheimer’s. The pitch has intrigued both healthcare investors and pharma venture arms.
By Jacob Bell • July 16, 2024 -
Getty Images
Revolution Medicines firms up Phase 3 trial plans with latest cancer drug data
Updated results show the biotech's RAS inhibitor shrank pancreatic tumors in 20% to 25% of study participants, but with high rates of side effects like rash and nausea.
By Ned Pagliarulo • July 15, 2024 -
Getty Images
Leqembi sales inch higher; Spark’s pivot leads to layoffs
Sales data suggest forecasts for the Alzheimer’s drug may be in reach. Elsewhere, a well-funded DNA sequencing startup landed one of the year’s larger private funding rounds.
By BioPharma Dive staff • July 12, 2024 -
Getty Images
AbbVie names new R&D head; Arcutis eczema cream approved
Roopal Thakkar will succeed Tom Hudson as AbbVie’s top scientist. Elsewhere, Skyhawk is advancing its Huntington’s drug and Zevra is preparing for an FDA advisory committee meeting.
By BioPharma Dive staff • July 10, 2024 -
Jerod Harris via Getty Images
Flagship raises $3.6B for biotech investing
The latest round of funding comes as the biotech company creator adds executives and prepares to grow more life sciences startups.
By Kristin Jensen • July 10, 2024 -
Permission granted by Amylyx Pharmaceuticals
Amylyx, with GLP-1 buy, doubles down on blood sugar drugs
Having recently withdrawn its only product from the market, Amylyx hopes to rebound with a drug that regulates GLP-1 activity and is poised to enter pivotal testing early next year.
By Jacob Bell • July 10, 2024 -
Getty Images
SciRhom pulls in $70M for a new type of immune disease drug
The Series A round will help the startup bring its lead candidate, an antibody aimed at the protein iRhom2, into human testing by the end of 2024.
By Gwendolyn Wu • July 9, 2024 -
Joe Raedle via Getty Images
HilleVax’s norovirus vaccine ineffective in large trial of infants
Shares in HilleVax plummeted after the company reported its experimental shot failed to meet the primary and secondary goals of the Phase 2b study.
By Delilah Alvarado • July 8, 2024 -
Getty Images
Ligand to buy Apeiron; Roche reports another TIGIT setback
Acquiring Apeiron will hand Ligand royalty rights on the neuroblastoma drug Qarziba. Elsewhere, CSL reported the first commercial treatment of patients in Europe with its gene therapy Hemgenix.
By BioPharma Dive staff • July 8, 2024 -
Permission granted by Myricx Bio
A London biotech raises $114M to hone a new ADC payload
Myricx Bio is developing a type of payload that it thinks could work in tumors resistant to the toxins contained in ADCs like Enhertu and Trodelvy.
By Gwendolyn Wu • July 8, 2024 -
Courtesy of CureVac
CureVac cuts jobs, licenses out vaccines to GSK
The mRNA specialist plans to eliminate 30% of its workforce as part of a restructuring that will prioritize “high-value” projects like its cancer vaccines.
By Jacob Bell • July 3, 2024 -
Getty Images
Beacon raises $170M for eye gene therapy; J&J confirms Carvykti survival benefit
Forbion led the startup’s Series B round. Elsewhere, Vertex got an FDA decision date for its “vanza triple” and Dupixent won a marketing green light in Europe for COPD.
By BioPharma Dive staff • July 3, 2024 -
Maddie Meyer via Getty Images
Moderna gets US funding for bird flu vaccine development
BARDA will provide Moderna with $176 million to advance late-stage testing of an H5 influenza shot, as health officials monitor animal outbreaks.
By Delilah Alvarado • July 2, 2024 -
Scott Olson via Getty Images
Eli Lilly inks another radiopharma deal, gaining option to buy startup
Under an arrangement with Radionetics, Lilly will have rights to acquire the San Diego biotechnology company for $1 billion.
By Delilah Alvarado • July 1, 2024 -
Courtesy of UniQure
UniQure, with sale of plant, outsources Hemgenix manufacturing
The gene therapy developer, which cut jobs in October, expects the sale of a Lexington, Massachusetts, facility to Genezen to lower its cash burn.
By Ned Pagliarulo • July 1, 2024 -
Getty Images
With revised IPO pitch, Artiva touts ‘natural killer’ cell therapy for autoimmune disease
Like many of its cell therapy peers, Artiva, which originally sought an IPO in 2021, has shifted its strategy to ride a wave of investor interest in autoimmune disease research.
By Ben Fidler • July 1, 2024 -
Kendall Davis/BioPharma Dive
Deep Dive10 clinical trials to watch in the second half of 2024
Study results are expected for two closely watched obesity drugs, while key tests await for a high-priced AbbVie acquisition and one of 2023’s largest IPOs.
By BioPharma Dive staff • July 1, 2024 -
Getty Images
PTC faces another Duchenne drug rejection; Coherus sells Humira biosimilar
European drug regulators voted for a third time not to renew the approval of Translarna. Elsewhere, Sanofi invested in a brain disease biotech and Esperion sold royalties to help pay off a loan.
By BioPharma Dive staff • June 28, 2024 -
Getty Images
Alumis cuts IPO size, but nets $250M for immune drug work
Alumis’ public offering comes during an uptick in interest in immune drugs. Still, the company sold fewer shares than intended, and added a concurrent private stock issuance to boost its total haul.
By Gwendolyn Wu • June 28, 2024 -
Courtesy of Bluebird bio
2seventy slims down with sale of hemophilia assets to Novo
Novo will pay $38 million in cash under the deal, which will also see 2seventy employees working on the program transfer to the Danish drugmaker.
By Ned Pagliarulo • June 27, 2024 -
Permission granted by Biohaven Ltd.
Deep DiveThese microscopic tunnels are a goldmine for new medicines
A growing cohort of biotechs, from Biohaven to Neurocrine to Jazz, hope research on ion channels will bring them new drugs and big business — much like it has done for Vertex.
By Jacob Bell • June 27, 2024
Previous
